Additionally, high Rad21 expression in patients with high‐grade luminal, basal, and human epidermal growth factor receptor 2 (HER2)‐positive breast cancers shortens the overall survival of patients and decreases chemosensitivity. This evidence concerns the gene ERBB2 and breast cancer.